Sun Pharma
Takeda’s zasocitinib shows high rates of skin clearance in phase 3 psoriasis studies
Globally, an estimated 64 million people have psoriasis, with about 80-90% of those having plaque psoriasis
J&J’s Tremfya approved by FDA for children with plaque psoriasis and psoriatic arthritis
The drug is the first IL-23 inhibitor approved for children from the age of six
FDA approves new presentation of Celltrion’s SteQeyma for paediatric psoriasis
The Stelara biosimilar now offers all dosage forms and strengths of its reference product
LEO and Reig Jofre partner to improve access to psoriasis therapy in Europe
Approximately 125 million people worldwide are affected by some form of the inflammatory condition
Bristol Myers Squibb shares five-year results for Sotyktu in plaque psoriasis
Plaque psoriasis affects up to 90% of patients with the immune-mediated disease
Bristol Myers Squibb’s Sotyktu shows promise in phase 3 psoriatic arthritis trials
The immune-mediated disease affects approximately 30% of people living with psoriasis
AbbVie to expand immunology pipeline with $200m Nimble Therapeutics acquisition
The deal includes an IL23R inhibitor in preclinical development for psoriasis and inflammatory bowel disease
Johnson & Johnson’s Tremfya shows promise in ‘special site’ plaque psoriasis
The immune-mediated disease affects more than 125 million people worldwide
Bristol Myers Squibb announces positive data for Sotyktu in moderate-to-severe psoriasis
At least 100 million people worldwide are affected by the immune-mediated disease
World Psoriasis Day: Almirall highlights impact of disease on patient well-being
Almost 77% of patients believe that psoriasis negatively affects their daily life and well-being
Listening and hearing – how patients’ online behaviour can help us to improve wellbeing in psoriasis.
The following article was developed using information gathered through primary and secondary desk research, including a recent Social Listening project conducted by our team at Mednet.
BMS launches campaign to highlight impact of psoriasis on patient well-being
An estimated 7.5 million people in the US are affected by some form of the condition